ECSP18060820A - Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano - Google Patents
Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decanoInfo
- Publication number
- ECSP18060820A ECSP18060820A ECSENADI201860820A ECDI201860820A ECSP18060820A EC SP18060820 A ECSP18060820 A EC SP18060820A EC SENADI201860820 A ECSENADI201860820 A EC SENADI201860820A EC DI201860820 A ECDI201860820 A EC DI201860820A EC SP18060820 A ECSP18060820 A EC SP18060820A
- Authority
- EC
- Ecuador
- Prior art keywords
- diaza
- carboxyethyl
- decane
- spiro
- oxo
- Prior art date
Links
- AKFDWOCIAWTVNG-UHFFFAOYSA-N 3-(8-amino-2-oxo-1,3-diazaspiro[4.5]decan-3-yl)propanoic acid Chemical class C(=O)(O)CCN1C(NC2(C1)CCC(CC2)N)=O AKFDWOCIAWTVNG-UHFFFAOYSA-N 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano, su preparación y su uso en medicamentos, en particular en el tratamiento del dolor.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16151011 | 2016-01-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP18060820A true ECSP18060820A (es) | 2018-08-31 |
Family
ID=55129632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI201860820A ECSP18060820A (es) | 2016-01-13 | 2018-08-13 | Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano |
Country Status (27)
| Country | Link |
|---|---|
| US (7) | US20170197919A1 (es) |
| EP (2) | EP3722283A1 (es) |
| JP (2) | JP6862457B2 (es) |
| KR (1) | KR20180100592A (es) |
| CN (1) | CN108699005B (es) |
| AR (1) | AR107361A1 (es) |
| AU (1) | AU2017207467B2 (es) |
| BR (1) | BR112018014302B1 (es) |
| CA (1) | CA3011175C (es) |
| CL (1) | CL2018001913A1 (es) |
| CO (1) | CO2018008445A2 (es) |
| CY (1) | CY1122882T1 (es) |
| DK (1) | DK3402783T3 (es) |
| EA (1) | EA037649B1 (es) |
| EC (1) | ECSP18060820A (es) |
| ES (1) | ES2803354T3 (es) |
| HR (1) | HRP20200656T1 (es) |
| HU (1) | HUE049374T2 (es) |
| IL (1) | IL260495B (es) |
| LT (1) | LT3402783T (es) |
| MX (1) | MX379201B (es) |
| PL (1) | PL3402783T3 (es) |
| PT (1) | PT3402783T (es) |
| RS (1) | RS60223B1 (es) |
| SI (1) | SI3402783T1 (es) |
| TW (1) | TWI635081B (es) |
| WO (1) | WO2017121646A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3722283A1 (en) * | 2016-01-13 | 2020-10-14 | Grünenthal GmbH | 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives |
| BR112018014303B1 (pt) | 2016-01-13 | 2023-10-03 | Grünenthal GmbH | Derivados de 3-((hetero-)aril)-alquil-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano |
| HRP20250176T1 (hr) | 2016-01-13 | 2025-04-11 | Grünenthal GmbH | Derivati 3-((hetero-)aril)-8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekana |
| SI3402785T1 (sl) | 2016-01-13 | 2020-07-31 | Gruenenthal Gmbh | Derivati 3-(karboksimetil)-8-amino-2-okso-1,3-diaza-spiro-(4.5)-dekana |
| CN108602778B (zh) | 2016-01-13 | 2021-12-10 | 格吕伦塔尔有限公司 | 8-氨基-2-氧代-1，3-二氮杂-螺-[4.5]-癸烷衍生物 |
| KR102866751B1 (ko) * | 2020-06-09 | 2025-10-01 | 삼성디스플레이 주식회사 | 축합환 화합물을 포함한 발광 소자 및 상기 발광 소자를 포함한 전자 장치 |
| TW202321258A (zh) * | 2021-08-02 | 2023-06-01 | 大陸商上海樞境生物科技有限公司 | 氧雜螺環類衍生物、製備方法及其用途 |
| US20240400537A1 (en) | 2023-04-25 | 2024-12-05 | Gruenenthal Gmbh | Cis-8-(3,5-difluorophenyl)-8-(dimethylamino)-1,3-diazaspiro[4.5]decan-2-one derivatives |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2734265B1 (fr) | 1995-05-17 | 1997-06-13 | Adir | Nouveaux composes spiro heterocycliques, leur procede de preparation et les compositions pharmaceutiques les contenant |
| EP1379252A4 (en) | 2001-04-18 | 2005-11-02 | Euro Celtique Sa | Nociceptin Analogs |
| DE10130020A1 (de) | 2001-06-25 | 2003-12-04 | Gruenenthal Gmbh | Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate |
| DE10210195B4 (de) | 2002-03-07 | 2005-12-15 | Schwarz Pharma Ag | Verwendung von 1,3-Diazaspiro-[4,5]decan-2,4-dithion zur Behandlung von Schmerz |
| DE10252667A1 (de) * | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| AU2004241134A1 (en) | 2003-05-23 | 2004-12-02 | Zealand Pharma A/S | Triaza-spiro compounds as nociceptin analogues and uses thereof |
| JO2676B1 (en) | 2004-04-06 | 2012-06-17 | جانسين فارماسوتيكا ان. في | Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines |
| EP2104665A2 (en) | 2006-10-19 | 2009-09-30 | F. Hoffmann-Roche AG | Imidazolone and imidazolidinone derivatives as 11b-hsd1 inhibitors for diabetes |
| CN101679430B (zh) | 2007-04-09 | 2013-12-25 | 詹森药业有限公司 | 用于治疗焦虑和抑郁症的作为orl-1受体的配体的1,3,8-三取代-1,3,8-三氮杂-螺[4.5]癸-4-酮衍生物 |
| CN103214376A (zh) | 2008-03-27 | 2013-07-24 | 格吕伦塔尔有限公司 | 取代的4-氨基环己烷衍生物 |
| TWI582092B (zh) | 2010-07-28 | 2017-05-11 | 歌林達股份有限公司 | 順式－四氫－螺旋（環己烷－１,１’－吡啶［３,４－b］吲哚）－４－胺－衍生物 |
| WO2014106238A1 (en) * | 2012-12-31 | 2014-07-03 | Fang, Qun, Kevin | Heterocyclic compounds and methods of use thereof |
| JP2017521488A (ja) | 2014-06-13 | 2017-08-03 | パーデュー、ファーマ、リミテッド、パートナーシップ | 複素環式モルフィナン誘導体及びその使用 |
| SI3402785T1 (sl) | 2016-01-13 | 2020-07-31 | Gruenenthal Gmbh | Derivati 3-(karboksimetil)-8-amino-2-okso-1,3-diaza-spiro-(4.5)-dekana |
| BR112018014303B1 (pt) | 2016-01-13 | 2023-10-03 | Grünenthal GmbH | Derivados de 3-((hetero-)aril)-alquil-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano |
| EP3722283A1 (en) | 2016-01-13 | 2020-10-14 | Grünenthal GmbH | 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives |
| CN108602778B (zh) | 2016-01-13 | 2021-12-10 | 格吕伦塔尔有限公司 | 8-氨基-2-氧代-1，3-二氮杂-螺-[4.5]-癸烷衍生物 |
-
2017
- 2017-01-13 EP EP20155667.7A patent/EP3722283A1/en not_active Withdrawn
- 2017-01-13 CN CN201780006500.8A patent/CN108699005B/zh not_active Expired - Fee Related
- 2017-01-13 KR KR1020187021561A patent/KR20180100592A/ko not_active Withdrawn
- 2017-01-13 RS RS20200519A patent/RS60223B1/sr unknown
- 2017-01-13 MX MX2018008640A patent/MX379201B/es unknown
- 2017-01-13 PT PT177004744T patent/PT3402783T/pt unknown
- 2017-01-13 LT LTEP17700474.4T patent/LT3402783T/lt unknown
- 2017-01-13 WO PCT/EP2017/025004 patent/WO2017121646A1/en not_active Ceased
- 2017-01-13 DK DK17700474.4T patent/DK3402783T3/da active
- 2017-01-13 JP JP2018536433A patent/JP6862457B2/ja not_active Expired - Fee Related
- 2017-01-13 PL PL17700474T patent/PL3402783T3/pl unknown
- 2017-01-13 EP EP17700474.4A patent/EP3402783B1/en active Active
- 2017-01-13 AR ARP170100096A patent/AR107361A1/es unknown
- 2017-01-13 TW TW106101123A patent/TWI635081B/zh active
- 2017-01-13 HU HUE17700474A patent/HUE049374T2/hu unknown
- 2017-01-13 EA EA201891610A patent/EA037649B1/ru unknown
- 2017-01-13 SI SI201730241T patent/SI3402783T1/sl unknown
- 2017-01-13 HR HRP20200656TT patent/HRP20200656T1/hr unknown
- 2017-01-13 ES ES17700474T patent/ES2803354T3/es active Active
- 2017-01-13 BR BR112018014302-2A patent/BR112018014302B1/pt not_active IP Right Cessation
- 2017-01-13 CA CA3011175A patent/CA3011175C/en active Active
- 2017-01-13 AU AU2017207467A patent/AU2017207467B2/en not_active Ceased
- 2017-01-13 US US15/405,482 patent/US20170197919A1/en not_active Abandoned
-
2018
- 2018-05-15 US US15/979,932 patent/US20180273491A1/en not_active Abandoned
- 2018-07-09 IL IL260495A patent/IL260495B/en unknown
- 2018-07-13 CL CL2018001913A patent/CL2018001913A1/es unknown
- 2018-08-13 EC ECSENADI201860820A patent/ECSP18060820A/es unknown
- 2018-08-13 CO CONC2018/0008445A patent/CO2018008445A2/es unknown
- 2018-12-03 US US16/207,676 patent/US20190100497A1/en not_active Abandoned
-
2019
- 2019-06-24 US US16/450,406 patent/US10793528B2/en active Active
-
2020
- 2020-05-06 CY CY20201100416T patent/CY1122882T1/el unknown
- 2020-08-31 US US17/007,374 patent/US20200399226A1/en not_active Abandoned
-
2021
- 2021-03-01 US US17/188,802 patent/US20210214315A1/en not_active Abandoned
- 2021-03-30 JP JP2021056938A patent/JP7148665B2/ja active Active
-
2023
- 2023-01-30 US US18/102,983 patent/US20230183184A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP18060848A (es) | Derivados de 3-((hetero)aril)-alquil-8-amino-2-oxo-1,3-diaza-espiro-[ 4.5]-decano | |
| ECSP18060820A (es) | Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano | |
| ECSP18060864A (es) | Derivados de 3-(carboximetil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano | |
| CL2018001911A1 (es) | Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano | |
| ECSP18060875A (es) | Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano | |
| CL2016002269A1 (es) | Moduladores alostéricos del núcleo proteico de la hepatitis b. | |
| MX2019012534A (es) | Combinacion de elafibranor o derivados del mismo con un agente anti-ehna, antifibrotico o anticolestasico. | |
| MX378273B (es) | Compuestos activos hacia bromodominios. | |
| MX386752B (es) | Agonistas del receptor farnesoide x y usos de los mismos. | |
| PL3896064T3 (pl) | Pochodne 4,6-diamino-chinolino-3-karbonitrylu jako modulatory cot w leczeniu choroby leśniowskiego-crohna i wrzodziejącego zapalenia jelita grubego | |
| MX386328B (es) | Derivados de maitansinoide, conjugados de los mismos, y metodos de uso. | |
| MX377340B (es) | Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares. | |
| CL2015002835A1 (es) | Nuevos derivados de piridina | |
| CL2015002897A1 (es) | Inhibidores de bace1 | |
| CY1125014T1 (el) | Υποκατεστημενα παραγωγα ξανθινης | |
| ECSP16086247A (es) | (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
| ECSP16086232A (es) | (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
| CO2018011420A2 (es) | Formulaciones líquidas de fosfaplatino | |
| UA115417U (xx) | Спосіб профілактики та лікування гіпоксичних змін при карбоперитонеумі | |
| CL2016000822A1 (es) | Tratamiento del cáncer con una combinación de plinabulina y taxano | |
| UA113284U (uk) | Спосіб лікування хворих на хронічний тонзиліт у поєднанні з атопічним дерматитом |